TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3050904

Group type: EXPERIMENTAL
Intervention: 1 mg inhaled gallopamil
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 10 mg inhaled gallopamil
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30418041

Group type: EXPERIMENTAL
Intervention: Exergames played for 2 weeks
Number of subjects: 337

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 337
Study: 29203509

Group type: EXPERIMENTAL
Intervention: Guided Self-Help: a low-intensity psychological intervention based on behavioural activation adapted for ASD
Number of subjects: 70

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 70
Study: 25520249

Group type: EXPERIMENTAL
Intervention: Sibutramine treatment with diet and exercise
Number of subjects: 9804

Group type: EXPERIMENTAL
Intervention: Sibutramine treatment
Number of subjects: 9804

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9804
Study: 24460649

Group type: EXPERIMENTAL
Intervention: PPAR α and PPAR γ polymorphisms (rs1800206, rs1805192, rs3856806)
Number of subjects: 820

Group type: COMPARATOR
Intervention: V-G haplotype (rs1800206, rs4253778)
Number of subjects: 820

Group type: COMPARATOR
Intervention: Pro-C haplotype (rs1805192, rs3856806)
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: A-T haplotype
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: P-T, A-C, A-T haplotypes
Number of subjects: 820
Study: 22481313

Group type: EXPERIMENTAL
Intervention: Higher-carbohydrate/lower-fat diet (55% CHO, 18% PRO, 27% FAT)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Lower-carbohydrate/higher-fat diet (43% CHO, 18% PRO, 39% FAT)
Number of subjects: 61
Study: 19531226

Group type: EXPERIMENTAL
Intervention: Pharmacy‐based blood pressure clinics led by peer health educators with feedback to family physicians
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Practice model
Number of subjects: 0
Study: 18166695

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention (3 times a week group exercise, 6 hours of fall prevention education, comprehensive falls risk assessment results sent to primary health care provider)
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 453

Group type: COMPARATOR
Intervention: Control group (written materials on falls prevention)
Number of subjects: 453
Study: 15468574

Group type: COMPARATOR
Intervention: Single dose of albendazole (400 mg)
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Nitazoxanide (1.2 g single dose)
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Nitazoxanide (15 mg/kg/day for three days)
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Nitazoxanide (three-day regimen)
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Nitazoxanide (single dose)
Number of subjects: 786

Group type: COMPARATOR
Intervention: Albendazole (single dose)
Number of subjects: 786
Study: 11799281

Group type: EXPERIMENTAL
Intervention: Milk containing Lactobacillus rhamnosus GG (LGG)
Number of subjects: 594

Group type: COMPARATOR
Intervention: Normal milk (Control)
Number of subjects: 594
Study: 9660039

Group type: EXPERIMENTAL
Intervention: Iron protein succinylate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Iron hydroxide polymaltose complex
Number of subjects: 100
Study: 7635580

Group type: EXPERIMENTAL
Intervention: Preoperative suggestions
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pre- and perioperative suggestions
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Perioperative suggestions only
Number of subjects: 60

Group type: COMPARATOR
Intervention: Matched control group
Number of subjects: 60
Study: 2100983

Group type: EXPERIMENTAL
Intervention: Parenteral cefoxitin (given in three divided doses)
Number of subjects: 197

Group type: COMPARATOR
Intervention: No parenteral antibiotics (control group)
Number of subjects: 197
Study: 150816

Group type: EXPERIMENTAL
Intervention: 5% sulfur in Triton X‐100 vehicle
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 5% sulfur in carbomer 934P vehicle
Number of subjects: 52

Group type: COMPARATOR
Intervention: Triton X‐100 vehicle (control)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Dry patch test (control)
Number of subjects: 52
Study: 30674360

Group type: EXPERIMENTAL
Intervention: SCP NF
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: θ/β NF
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (attention skills training)
Number of subjects: 30
Study: 31421668

Group type: EXPERIMENTAL
Intervention: Physiotherapy alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physiotherapy combined with corticosteroid injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28756791

Group type: EXPERIMENTAL
Intervention: Smartphone application intervention for physical activity
Number of subjects: 0
Study: 25636341

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg once daily
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study: 25835233

Group type: EXPERIMENTAL
Intervention: Vitamin D3 tablets (2000 IU/day) for six months
Number of subjects: 126
Study: 22307529

Group type: EXPERIMENTAL
Intervention: 0.1% gentamicin cream
Number of subjects: 16

Group type: COMPARATOR
Intervention: 2% lidocaine jelly
Number of subjects: 16
Study: 19542998

Group type: EXPERIMENTAL
Intervention: Esmolol (0.5 mg/kg) during sevoflurane anesthesia
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline during sevoflurane anesthesia
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Esmolol (0.5 mg/kg) during desflurane anesthesia
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline during desflurane anesthesia
Number of subjects: 80
Study: 17324413

Group type: EXPERIMENTAL
Intervention: Stent retrieval (group B)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Stents left in place (group A)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Stents left in place (non-randomized group)
Number of subjects: 46
Study: 15149253

Group type: EXPERIMENTAL
Intervention: Speed stress with adaptive tracking algorithm to adjust response deadlines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Speeded decisions based on several types of information
Number of subjects: 0
Study: 11605289

Group type: EXPERIMENTAL
Intervention: Rotating tibia component
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fixed polyethylene inlay
Number of subjects: 0
Study: 9801975

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin during orthotopic liver transplantation (OLT)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin during cardiac surgery
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Extracorporeal circulation during cardiac surgery
Number of subjects: 47

Group type: COMPARATOR
Intervention: High-dose aprotinin
Number of subjects: 47
Study: 7925538

Group type: EXPERIMENTAL
Intervention: Color flow Doppler sonography (CFDS)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Voiding cystourethrography (VCU)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Follow-up after antireflux operations
Number of subjects: 21
Study: 2154316

Group type: EXPERIMENTAL
Intervention: Chemotherapy for nonseminomatous germ cell tumors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Staging systems for germ cell tumors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic approaches (surgery, chemotherapy, surgery plus chemotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinically relevant staging systems
Number of subjects: 0
Study: 842382

Group type: EXPERIMENTAL
Intervention: Levodopa treatment for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31145386

Group type: EXPERIMENTAL
Intervention: Game Profile-Based Training (GPBT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Small-Sided Games (SSG)
Number of subjects: 20
Study: 30786861

Group type: EXPERIMENTAL
Intervention: 12-week moderate-intensity exercise program (Borg perceived rating scale 13-14), at least three times weekly; one supervised group training and two home-based sessions
Number of subjects: 724

Group type: COMPARATOR
Intervention: Standard prenatal care
Number of subjects: 724
Study: 28005705

Group type: EXPERIMENTAL
Intervention: Distal treatment applied mainly in the distal branches beyond the main bifurcation (n = 24)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Conventional treatment restricted to the main renal artery (n = 21)
Number of subjects: 51
Study: 26423500

Group type: EXPERIMENTAL
Intervention: Group 2: sectioned and precontoured metal matrix and elastic wedge (G2‐SME)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group 1: metal matrix coupled to a carrier matrix and wood wedge (G1‐MMW)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group 3: polyester strip and reflective wedge (G3‐PMR)
Number of subjects: 30
Study: 23237479

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (20 min, 1 mA) to the left dorsolateral prefrontal cortex (dlPFC)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 46
Study: 21665047

Group type: EXPERIMENTAL
Intervention: 15-mg modified-release tablet of metoclopramide every 12 hours
Number of subjects: 26

Group type: COMPARATOR
Intervention: 10-mg immediate-release tablet of metoclopramide every 8 hours
Number of subjects: 26
Study: 17941873

Group type: EXPERIMENTAL
Intervention: BIAsp 30 + met/pio
Number of subjects: 181

Group type: COMPARATOR
Intervention: met/pio
Number of subjects: 181
Study: 16455425

Group type: EXPERIMENTAL
Intervention: Marathon running
Number of subjects: 45
Study: 16342231

Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 43
Study: 14597948

Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: tirofiban
Number of subjects: 20

Group type: COMPARATOR
Intervention: aspirin plus clopidogrel
Number of subjects: 20
Study: 10227336

Group type: EXPERIMENTAL
Intervention: Albuterol delivered via breath-actuated inhaler (Spiros)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Albuterol delivered via MDI (Ventolin)
Number of subjects: 60
Study: 9156929

Group type: EXPERIMENTAL
Intervention: Benign mastopathy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 1914371

Group type: EXPERIMENTAL
Intervention: 25 mg phenylpropanolamine and 250 mg caffeine
Number of subjects: 6

Group type: COMPARATOR
Intervention: 25 mg phenylpropanolamine
Number of subjects: 6

Group type: COMPARATOR
Intervention: 250 mg caffeine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 7048589

Group type: EXPERIMENTAL
Intervention: Cholecystectomy without drainage
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cholecystectomy with drainage
Number of subjects: 100
Study: 29797914

Group type: EXPERIMENTAL
Intervention: Catgut implantation at stellate ganglion combined with oral administration of alendronate sodium
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral administration of alendronate sodium alone
Number of subjects: 60
Study: 28319454

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Live attenuated hepatitis A vaccine
Number of subjects: 332
Study: 26151336

Group type: EXPERIMENTAL
Intervention: Ingesting 10 g fat
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ingesting 40 g fat
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (10 g fat)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (40 g fat)
Number of subjects: 16
Study: 23964055

Group type: EXPERIMENTAL
Intervention: 400 g high-glucoraphanin (HG) broccoli
Number of subjects: 0

Group type: COMPARATOR
Intervention: 400 g standard broccoli
Number of subjects: 0

Group type: COMPARATOR
Intervention: 400 g peas
Number of subjects: 0
Study: 19729203

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 6 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (mentally healthy women)
Number of subjects: 20
Study: 18949312

Group type: EXPERIMENTAL
Intervention: Flavor-containing dentifrice
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-flavor-containing dentifrice
Number of subjects: 50
Study: 16546473

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (ROS) 4 mg daily for 12 weeks
Number of subjects: 21
Study: 12775730

Group type: EXPERIMENTAL
Intervention: FOLFOX4
Number of subjects: 463

Group type: COMPARATOR
Intervention: LV5FU2
Number of subjects: 463
Study: 10703675

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/d)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 23
Study: 9381523

Group type: EXPERIMENTAL
Intervention: Candoxatrilat (100 mg i.v.)
Number of subjects: 12
Study: 8222497

Group type: EXPERIMENTAL
Intervention: Oral administration of contraceptive pill (250 micrograms levonorgestrel and 50 micrograms ethinyl estradiol)
Number of subjects: 819

Group type: EXPERIMENTAL
Intervention: Vaginal administration of contraceptive pill (250 micrograms levonorgestrel and 50 micrograms ethinyl estradiol)
Number of subjects: 819
Study: 2949683

Group type: EXPERIMENTAL
Intervention: 2% miconazole powder
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Talcum powder with 2% salicylic acid and boric acid
Number of subjects: 208
Study: 29961187

Group type: EXPERIMENTAL
Intervention: Chromium picolinate (Cr‐Pic) at 1.2 mg kg‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Chromium picolinate (Cr‐Pic) at 1.8 mg kg‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Chromium picolinate (Cr‐Pic) at 1.2 mg kg‐1 and 1.8 mg kg‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Chromium picolinate (Cr‐Pic)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Low-protein diet with 1.8 mg kg‐1 Cr
Number of subjects: 120
Study: 27346880

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 0.5 mg/day for 6 months
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 25545924

Group type: EXPERIMENTAL
Intervention: Walking school bus intervention
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 8
Study: 22365897

Group type: COMPARATOR
Intervention: Oxycodone 10mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Alprazolam 0.5mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5mg + Oxycodone 10mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 20550052

Group type: EXPERIMENTAL
Intervention: 17 alpha‐hydroxyprogesterone caproate (17P)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 193
Study: 18656072

Group type: EXPERIMENTAL
Intervention: Decisional balance exercise promoting CT and NGC screening
Number of subjects: 192
Study: 15906783

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg MR o.d.) for 12 weeks
Number of subjects: 261
Study: 12712350

Group type: EXPERIMENTAL
Intervention: Tennis matches (TEC)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Simulated orienteering (OTC)
Number of subjects: 31
Study: 10856736

Group type: EXPERIMENTAL
Intervention: Milrinone infusion for 48 hours
Number of subjects: 951

Group type: COMPARATOR
Intervention: Standard therapy (placebo infusion for 48 hours)
Number of subjects: 951
Study: 8674324

Group type: EXPERIMENTAL
Intervention: Lisofylline (CT1501R)
Number of subjects: 69

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 69

Group type: COMPARATOR
Intervention: At-risk patients who did not develop ARDS (group A)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: At-risk patients who developed ARDS (group B)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Patients with ARDS at the time of admission (group C)
Number of subjects: 69
Study: 1909228

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 116

Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 116
Study: 6347152

Group type: EXPERIMENTAL
Intervention: Topical oxymetazoline hydrochloride 0.025%
Number of subjects: 2
Study: 30325891

Group type: EXPERIMENTAL
Intervention: Inactivated quadrivalent influenza vaccine (IIV4)
Number of subjects: 433

Group type: COMPARATOR
Intervention: Control (no vaccine)
Number of subjects: 433
Study: 29136227

Group type: EXPERIMENTAL
Intervention: PGS (Day-3 cleavage-stage)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control (no PGS)
Number of subjects: 99
Study: 27129842

Group type: EXPERIMENTAL
Intervention: Palonosetron (PALO)
Number of subjects: 1114

Group type: COMPARATOR
Intervention: Granisetron (GRA)
Number of subjects: 1114
Study: 23727146

Group type: EXPERIMENTAL
Intervention: Hypoxic gas mixture for 30 min
Number of subjects: 12

Group type: COMPARATOR
Intervention: Room air for 30 min
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hypoxic gas mixture for 60 min
Number of subjects: 12

Group type: COMPARATOR
Intervention: Room air for 60 min
Number of subjects: 12
Study: 23155956

Group type: EXPERIMENTAL
Intervention: Gabapentin 100 mg at night and 300 mg orally two hours before surgery
Number of subjects: 61

Group type: COMPARATOR
Intervention: Multivitamin (control group)
Number of subjects: 61
Study: 20479421

Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 668

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Both study arms
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Presence of CA
Number of subjects: 668
Study: 18833819

Group type: EXPERIMENTAL
Intervention: Liquid-based cytology (LBC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional cervical testing (CCT)
Number of subjects: 0
Study: 16101609

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 150

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 150
Study: 11921115

Group type: EXPERIMENTAL
Intervention: LDEE-CD (levodopa ethylester-carbidopa)
Number of subjects: 62

Group type: COMPARATOR
Intervention: LD-CD (levodopa-carbidopa)
Number of subjects: 62
Study: 10733041

Group type: EXPERIMENTAL
Intervention: Low birth weight children
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Childhood body mass index
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Maternal blood pressure outside pregnancy
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Hemoglobin during pregnancy
Number of subjects: 518

Group type: COMPARATOR
Intervention: Other maternal characteristics (blood pressure, smoking, weight gain, weight at 20 weeks' gestation, glycemia) and size at birth (birth weight, ponderal index, head circumference/length ratio, small for gestational age)
Number of subjects: 518
Study: 8866628

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Captopril (CAPT)
Number of subjects: 30
Study: 1734386

Group type: EXPERIMENTAL
Intervention: Erythromycin (10 days of oral treatment)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Mupirocin (10 days of topical treatment)
Number of subjects: 93
Study: 6093182

Group type: EXPERIMENTAL
Intervention: Desimipramine (DMI) 50 mg IV
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Desimipramine (DMI) 25 mg IV
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Chlorimipramine (CI) 25 mg IV
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sulpiride (100 mg IV)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Diazepam (10 mg IV)
Number of subjects: 36
Study: 31283957

Group type: EXPERIMENTAL
Intervention: Angelica keiskei intake
Number of subjects: 20
Study: 29336628

Group type: EXPERIMENTAL
Intervention: Dietary supplement containing 178 mg satiereal, 100 mg naringin, and 2,000 IU vitamin D3 daily (SUPP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 20
Study: 26603744

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 2348

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2348

Group type: EXPERIMENTAL
Intervention: NT-proBNP addition to models
Number of subjects: 2348
Study: 25380092

Group type: EXPERIMENTAL
Intervention: Ablative SP CO2 laser
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ablative fractional CO2 laser
Number of subjects: 20
Study: 22185496

Group type: EXPERIMENTAL
Intervention: Socially Evaluated Cold Pressor Test (SECPT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Warm water control procedure
Number of subjects: 40
Study: 20454497

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg dose)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 17507738

Group type: EXPERIMENTAL
Intervention: 50 g/d of protein
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 100 g/d of protein
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 200 g/d of protein
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All protein intakes (50 g, 100 g, 200 g)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 6-day modification of protein intake
Number of subjects: 10
Study: 16160649

Group type: EXPERIMENTAL
Intervention: Delayed FDG PET imaging
Number of subjects: 86

Group type: COMPARATOR
Intervention: Early FDG PET imaging
Number of subjects: 86
Study: 11803082

Group type: EXPERIMENTAL
Intervention: TA‐CD therapeutic vaccine at 13 microg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: TA‐CD therapeutic vaccine at 82 microg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: TA‐CD therapeutic vaccine at 709 microg
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: TA‐CD therapeutic vaccine (all doses combined)
Number of subjects: 34
Study: 12176783

Group type: EXPERIMENTAL
Intervention: Primary single-agent epirubicin (120 mg/m(2) every 3 weeks for three cycles)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Conservative surgery and breast irradiation
Number of subjects: 319
Study: 9825179

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (120 mg/d) for 28 days
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 7854512

Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective adsorption
Number of subjects: 0
Study: 2496977

Group type: EXPERIMENTAL
Intervention: Flecainide acetate 400 mg
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38